3Simon G E, Psaty B M, Hrachoves J B, et al. Principles for evidence-based drug formulary policy [J]. J Gen Intern Med, 2005, 20 (10): 964-968.
4Bielory L. USP Model Guidelines Expert Committee. United States pharmacopeia development of the Medicare model formulary guidelines [J]. Am J Geriatr Cardiol, 2005, 14 (6): 301-307.
5Lehunann D F, Guharoy, Page N, et al. Formulary rnanagement as a tool to improve medication use and gain physician support[J].AmJ Health Syst Pharm, 2007, 64 (5): 464-466.
6Smetana G W, Davis R B, Phillips R S. Factors that influence patient response to requests to change to a unified restrictive formulary[J]. J Gen Intern Med, 2004, 19 (12): 1212-1219.
7Olson B M. Approaches to pharmacy benefit management and the impact of consumer cost sharing [J] . Clin Ther, 2003, 25 (1): 250-272.
8Schiff P L Jr, Srinivasan V S, Giancaspro G I, et al. The development of USP botanical dietary supplement monographs, 1995-2005 [J].J Nat Prod, 2006, 69 (3): 464-472.
9Cantrill J A. Measuring the appropriateness of long-term prescribing in United Kingdom general practice-is the British National Formulary the "gold standard"? [J].J Clin Pharm Ther, 2000, 25 (5): 341-346.
10Elias-Jones A, Rylance G. The launch of the British National Formulary for Children [J]. Arch Dis Child, 2005, 90 (10) : 997-998.
